ABSTRACT
Most COVID-19 vaccines have proved to be effective to combat the pandemic and to prevent severe disease but their distribution proceeds in a context of global vaccine shortage Their uneven distribution favors the appearance of new variants of concern, as the highly transmissible Delta variant, affecting especially non-vaccinated people. We consider that devising reliable models to analyse the spread of the different variants is crucial. These models should include the effects of vaccination as well as non-pharmaceutical measures used to contain the pandemic by modifying social behaviour. In this work, we present a stochastic geographical model that fulfills these requirements. It consists of an extended compartmental model that includes various strains and vaccination strategies, allowing to study the emergence and dynamics of the new COVID-19 variants. The models conveniently separates the parameters related to the disease from the ones related to social behavior and mobility restrictions. The geographical spread of the virus is modeled taking into account the actual population distribution in any given country of interest. Here we choose the UK as model system, taking advantage of the reliable available data, in order to fit the recurrence of the currently prevalent variants. Our computer simulations allow to describe some global features observed in the daily number of cases, as the appearance of periodic waves and the features that determine the prevalence of certain variants. They also provide useful predictions aiming to help planning future vaccination boosters. We stress that the model could be applied to any other country of interest.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
RAB, MN and NLB acknowledge support from The National Autonomous University of Mexico (UNAM) and Alianza UCMX of the University of California (UC), through the project included in the Special Call for Binational Collaborative Projects addressing COVID-19. RAB was financially supported by Conacyt through project 283279 and PAPIIT, UNAM project IG200121. MN was partially supported by CONICET. NLB and PGB acknowledge support from project 03 NAC 009/21 from CITEDEF
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Code available on request
